{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166288601",
    "name" : "Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",
    "alternateDrugAvailable" : false,
    "cancerGenome" : false,
    "crossReferences" : [],
    "descriptiveVideoId" : "UWRTwdNT1ek",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1452065080,
        "date" : "2023-04-10T14:27:30.938-07:00",
        "description" : "added CPIC guideline publication",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452506962,
        "date" : "2024-06-25T01:19:36.027-07:00",
        "description" : "Added video",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15143242,"title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564324","crossReferences":[{"id":1452680439,"resource":"PubMed Central","resourceId":"PMC10564324","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564324"},{"id":1452064840,"resource":"PubMed","resourceId":"37032427","_url":"https://www.ncbi.nlm.nih.gov/pubmed/37032427"},{"id":1452064841,"resource":"DOI","resourceId":"10.1002/cpt.2903","_url":"http://dx.doi.org/10.1002%2Fcpt.2903"}],"objCls":"Literature","pubDate":"2023-07-01T00:00:00-07:00","terms":[{"id":1454108620,"resource":"ClinPGx Tags","term":"CPIC","termId":"pgkbTags:1454108620"},{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA449015",
        "name" : "citalopram",
        "version" : 23
      },
      {
        "objCls" : "Chemical",
        "id" : "PA165958374",
        "name" : "desvenlafaxine",
        "version" : 10
      },
      {
        "objCls" : "Chemical",
        "id" : "PA10066",
        "name" : "duloxetine",
        "version" : 9
      },
      {
        "objCls" : "Chemical",
        "id" : "PA10074",
        "name" : "escitalopram",
        "version" : 13
      },
      {
        "objCls" : "Chemical",
        "id" : "PA449673",
        "name" : "fluoxetine",
        "version" : 21
      },
      {
        "objCls" : "Chemical",
        "id" : "PA449690",
        "name" : "fluvoxamine",
        "version" : 10
      },
      {
        "objCls" : "Chemical",
        "id" : "PA166182150",
        "name" : "levomilnacipran",
        "version" : 3
      },
      {
        "objCls" : "Chemical",
        "id" : "PA164752812",
        "name" : "milnacipran",
        "version" : 8
      },
      {
        "objCls" : "Chemical",
        "id" : "PA450801",
        "name" : "paroxetine",
        "version" : 17
      },
      {
        "objCls" : "Chemical",
        "id" : "PA451333",
        "name" : "sertraline",
        "version" : 15
      },
      {
        "objCls" : "Chemical",
        "id" : "PA451866",
        "name" : "venlafaxine",
        "version" : 10
      },
      {
        "objCls" : "Chemical",
        "id" : "PA165958365",
        "name" : "vilazodone",
        "version" : 5
      },
      {
        "objCls" : "Chemical",
        "id" : "PA166122595",
        "name" : "vortioxetine",
        "version" : 5
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA312",
        "symbol" : "SLC6A4",
        "name" : "solute carrier family 6 member 4",
        "version" : 145
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1452007480,
      "html" : "<p>There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on <em>SLC6A4</em> genotypes.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1452007481,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/\" target=\"_blank\">CPIC&reg; guideline for <em>CYP2D6</em>, <em>CYP2C19</em>, <em>CYP2B6</em>, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants</a>.</p>\n<h3 id=\"february-2023\">February 2023</h3>\n<p>The authors of the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/\" target=\"_blank\">CPIC&reg; guideline for <em>CYP2D6</em>, <em>CYP2C19</em>, <em>CYP2B6</em>, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants</a> evaluated the available evidence for the use of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran in patients carrying <em>SLC6A4</em> variants.</p>\n<ul>\n<li>\n<p>Excerpts from the guideline:</p>\n<ul>\n<li>&quot;Clinical recommendations are not provided for serotonin reuptake inhibitor antidepressants based on <em>HTR2A</em> and <em>SLC6A4</em> genotypes because the evidence supporting an association is mixed and/or insufficient to support clinical validity and utility at this time (CPIC level C-no recommendation).&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427.pdf\" target=\"_blank\">CPIC&reg; Guideline for for <em>CYP2D6</em>, <em>CYP2C19</em>, <em>CYP2B6</em>, <em>SLC6A4</em>, and <em>HTR2A</em> Genotypes and Serotonin Reuptake Inhibitor Antidepressants</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427-supplement.pdf\" target=\"_blank\">2023 supplement</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-dosing-recommendations-for-citalopram-escitalopram-fluoxetine-fluvoxamine-paroxetine-sertraline-duloxetine-venlafaxine-desvenlafaxine-vilazodone-vortioxetine-levomilnacipran-and-milnacipran-based-on-slc6a4-genotype\">Table 1: Dosing recommendations for citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, and milnacipran based on <em>SLC6A4</em> genotype</h3>\n<p><em>Adapted from Table S8 of the guideline supplement.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Genotype</th>\n<th>Implications</th>\n<th>Recommendations</th>\n<th>Classification of<br/>recommendation</th>\n<th>Considerations</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>5HTTLPR L</td>\n<td>Mixed evidence for the effect of genetic variability on SSRI response, remission, or side effects.</td>\n<td>No action recommended based on genotype for SSRIs because of insufficient evidence supporting clinical use.</td>\n<td>No recommendation</td>\n<td>Some meta-analyses show a small-to-medium and statistically significant SSRI antidepressant class association with increased response, increased remission, or decreased side effects in persons of European descent. These findings do not appear to be generalizable across other population groups. The impact of these associations with SSRI dose are unclear. There are insufficient data to confirm the presence or absence of an SLC6A4 genotype association with non-SSRI response, remission, or side effects. There remains a lack of clarity regarding how to translate this into clinical action.</td>\n</tr>\n<tr>\n<td>Intron 2 VNTR 12 repeat</td>\n<td>Mixed evidence for the effect of genetic variability on SSRI response or remission.</td>\n<td>No action recommended based on genotype for SSRI because of insufficient evidence supporting clinical use.</td>\n<td>No recommendation</td>\n<td></td>\n</tr>\n<tr>\n<td>Other variants</td>\n<td>No effect or insufficient evidence for SSRI response, remission, or side effects.</td>\n<td>No action recommended based on genotype for SSRIs because of insufficient evidence supporting clinical use.</td>\n<td>No recommendation</td>\n<td></td>\n</tr>\n</tbody>\n</table>\n",
      "version" : 0
    },
    "version" : 1
  }
}